← Back to Search

Coping and Communication Skills Training for Gynecologic Cancers

N/A
Recruiting
Led By Sharon L Manne, PhD
Research Sponsored by Rutgers, The State University of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with Stage 2 or higher cervical cancer or experienced a recurrence within the past 5 years;
Has internet access, able to view the online intervention sessions and attend telephone or video/telehealth chats to discuss the session content and provide feedback;
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, two and 6 months post-baseline
Awards & highlights

Study Summary

This trial found that Journey Ahead was helpful in teaching communication and coping skills to women with gynecologic cancers.

Who is the study for?
This trial is for women over 18 who've been diagnosed with various gynecological cancers, including uterine, ovarian, and cervical cancer. Participants should be within 5 years post-cancer surgery or treatment like chemo or radiation and must have internet access to view online sessions.Check my eligibility
What is being tested?
The 'Journey Ahead' intervention is being tested to see if it helps improve coping and communication skills in women with gynecologic cancers. It involves informational sessions viewed online followed by discussions via phone or video chat.See study design
What are the potential side effects?
Since this study focuses on an informational intervention rather than a medical treatment, traditional physical side effects are not expected. However, discussing sensitive topics may cause emotional discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I was diagnosed with Stage 2 or higher cervical cancer or had a recurrence in the last 5 years.
Select...
I can access the internet and participate in online sessions and telehealth chats.
Select...
I am mostly active and can carry out my daily activities.
Select...
I've had cancer treatment or surgery within the last 5 years.
Select...
I was diagnosed within the last 5 years and agree to participate.
Select...
I was diagnosed with ovarian, peritoneal, or fallopian tube cancer or had a recurrence in the last 5 years.
Select...
I was diagnosed with advanced or recurrent endometrial cancer in the last 5 years.
Select...
I have been diagnosed with uterine cancer or it has come back in the last 5 years.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, two and 6 months post-baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, two and 6 months post-baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cancer specific distress "change" is being assessed over the time points
Depressive symptoms "change" is being assessed
Psychological distress and well being "change" is being assessed
+1 more
Secondary outcome measures
Coping "change" is being assessed
Emotional Acceptance scale Change
Holding back from sharing concerns
+5 more
Other outcome measures
Demographic information
Medical Outcome- time since diagnosis
Medical Outcome- use of medication for pain, depression, anxiety
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Journey AheadExperimental Treatment2 Interventions
Experimental: Journey Ahead intervention focusing on coping and communication skill development during the course of 8 sessions and 6 phone calls.

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor
426 Previous Clinical Trials
64,231 Total Patients Enrolled
5 Trials studying Ovarian Cancer
393 Patients Enrolled for Ovarian Cancer
Sharon L Manne, PhDPrincipal InvestigatorRutgers Cancer Institute of New Jersey
2 Previous Clinical Trials
1,164 Total Patients Enrolled

Media Library

Journey Ahead Clinical Trial Eligibility Overview. Trial Name: NCT05220033 — N/A
Ovarian Cancer Research Study Groups: Journey Ahead
Ovarian Cancer Clinical Trial 2023: Journey Ahead Highlights & Side Effects. Trial Name: NCT05220033 — N/A
Journey Ahead 2023 Treatment Timeline for Medical Study. Trial Name: NCT05220033 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this trial taking on new participants?

"Per clinicaltrials.gov, this study is presently recruiting participants and was first advertised on July 14th 2020 with the latest update occuring on July 27th 2022."

Answered by AI

What is the uppermost limit of participants involved in this research endeavor?

"Affirmative. Clinicaltrials.gov displays that this investigation, which was originally published on July 14th 2020, is currently seeking participants from one site and hopes to recruit 30 individuals in total."

Answered by AI

What is the main purpose behind this research endeavor?

"This medical trial has been designed to measure shifts in depressive symptoms over a baseline period and two follow-up visits 6 months later. Secondary outcomes of interest include physical impairment, psychological flexibility, and positive emotional expression. Physical limitation is evaluated using the CARES questionnaire; acceptance & action with AAQ-II; while emotional expressiveness will be determined by the King & Emmons survey."

Answered by AI
~1 spots leftby May 2024